Developments Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer Faron Pharmaceuticals (AIM: FARN; First North: FARON) has announced the publication of a comprehensive review article in the peer-reviewed journal Immunotherapy detailing the potential of the company’s lead candidate... January 29, 2026